Cancer Research

The importance of partnership and innovation in oncology

22 January 2021

Fostering synergies to accelerate innovation in oncology and make it attractive for partners has been the MATWIN motto for over a decade, writes CEO Lucia Robert, MATWIN who outlines the organisations’s work MATWIN is a French open-innovation platform dedicated to supporting innovation in oncology. For more than ten years, its goal has been to help […]

Syngeneic mouse models for preclinical immuno-oncology

19 January 2021

The advent of immuno-oncology has necessitated changes in the types of animal models used in oncology drug discovery. Syngeneic models — inbred mice bearing an engrafted tumour derived from a genetically identical mouse strain — are invaluable preclinical research tools that enable tumour studies in the context of a complete and functional immune system. These […]

How hard-to-treat cancers may benefit from new drug that targets pathways

18 January 2021

After decades of no luck, scientists have finally found a way to target the KRAS mutation – a common mutation found in several hard-to-treat cancers – according to a new study funded by Cancer Research UK and Wellcome. By targeting two components of the KRAS signalling pathway, a new drug was much better at stopping the growth […]

Promising new treatment strategy for men with drug-resistant prostate cancer

12 January 2021

A new experimental drug could offer a promising approach to treating men with advanced prostate cancer which does not respond to existing treatments, or develops resistance to them, researchers report. The study reveals the chemical structure of a new targeted drug known as CCS1477 and its method of action – and suggests it could be […]

Common drug may protect hearts from damage caused by breast cancer chemotherapy

6 January 2021

New research from UHN’s Peter Munk Cardiac Centre (PMCC) shows statins, commonly prescribed to lower cholesterol and reduce the risk of heart disease and stroke, may also protect the heart from damaging side-effects of early breast cancer treatment. Published in the Journal of the American Heart Association, an observational study found women already taking statins […]

Study examines immune response to COVID-19 in cancer patients

5 January 2021

A new study funded by Cancer Research UK shows that the immune response to COVID-19 is the same in people with solid tumours compared to those without cancer. However, blood cancer patients varied in their ability to respond to the virus, with many unable to shake off the virus for up to 90 days after […]

Combined approach could boost breast cancer immunotherapy, study suggests

4 January 2021

Activating an immune signalling pathway best known for fighting viral and bacterial infections can boost the ability of genetically engineered T cells to eradicate breast cancer in mice, according to a new study by researchers at the University of North Carolina. The study, published in the Journal of Experimental Medicine (JEM), suggests that CAR T […]

International consortium awarded grant for first-in-class metastatic cancer treatment

18 December 2020

ONA Therapeutics, Absolute Antibody and RIC – three leading European companies in the biotech landscape – have been awarded a Eurostars grant for a two-year project that will develop a proprietary biological drug with a unique mode of action for the treatment of various types of metastatic cancers. Taking the lives of more than 9 […]

New 3D protein complex structure could be ‘a treasure map’ for new treatments

18 December 2020

Scientists have created a three-dimensional map of a complex of molecules that plays a fundamental role in life – and which when it goes wrong is linked to increased sensitivity to viral infections and neurodegenerative diseases. Their research has revealed the structure of the protein complex in human cells in stunning detail and shown precisely […]

New analysis method for predicting the risks and effects of immunotherapy

15 December 2020

In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphocytic leukaemia. It is  thought that this analysis method could pave the way for breakthroughs in immunotherapy research and treatment. Immunotherapy – […]

Next »

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free